1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bayer AG (Bayer) is a global healthcare company. It is an investment holding company for its group companies, namely, Bayer HealthCare, Bayer CropScience, Bayer MaterialScience, Bayer Business Services, Bayer Technology Services and Currenta. It focuses on the development, production and commercialization of healthcare products, nutritional supplements and specialty materials. The product portfolio of the company comprises animal health products, consumer care products, medical care products, pharmaceuticals, fungicides, insecticides, herbicides, polyurethanes, polycarbonates, coatings, adhesives and specialties. It caters to pharmaceutical, agricultural and polymer industries. The company also offers information technology (IT) and business services such as IT infrastructure and application, procurement and logistics, process development, plant engineering and construction, utility supply and waste management infrastructure services. It operates through a network of subsidiaries in Asia-Pacific, Europe, the US, and other markets such as Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG Key Recent Developments

Aug 27, 2015: CINDE Announces: Bayer Opened Its First Medical Devices Plant in Costa Rica
Jul 29, 2015: Bayer Significantly Improves Earnings
Jun 19, 2015: Bayer Plans To Invest €4 Billion In R&D In 2015
Jun 18, 2015: One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015
Jun 15, 2015: Bayer to Present Latest Advances in Hemophilia Research at the ISTH 2015 Annual Congress in Toronto

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Bayer AG - Key Facts 6
Bayer AG - Key Employees 7
Bayer AG - Key Employee Biographies 10
Bayer AG - Major Products and Services 11
Bayer AG - Pharmaceutical Pipeline Products Data 14
Bayer AG, Pipeline Products by Therapy Area 14
Bayer AG, Pipeline Products by Development Phase 15
Bayer AG - History 23
Bayer AG - Company Statement 36
Bayer AG - Locations And Subsidiaries 38
Head Office 38
Other Locations and Subsidiaries 38
Joint Venture 48
Section 2 - Company Analysis 49
Bayer AG - Business Description 49
Bayer AG - Corporate Strategy 51
Bayer AG - SWOT Analysis 52
SWOT Analysis - Overview 52
Bayer AG - Strengths 52
Strength - Lead Segment - HealthCare Products 52
Strength - Strong In-house Research Expertise 52
Strength - Best-Selling Pharmaceuticals Products 53
Bayer AG - Weaknesses 54
Weakness - Product Side Effects 54
Bayer AG - Opportunities 55
Opportunity - Strategic Acquisitions 55
Opportunity - Strategic Expansion Initiatives 55
Bayer AG - Threats 56
Threat - Growing Parallel Trade 56
Threat - Government Regulations 56
Threat - Increasing Competitive Pressures 56
Bayer AG - Key Competitors 57
Section 3 - Company Financial Ratios 58
Financial Ratios - Capital Market Ratios 58
Financial Ratios - Annual Ratios 59
Performance Chart 61
Financial Performance 61
Financial Ratios - Interim Ratios 62
Financial Ratios - Ratio Charts 63
Section 4 - Company's Lifesciences, Power Financial Deals and Alliances 64
Bayer AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 64
Bayer AG, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 65
Bayer AG, Petrochemicals, Deals By Year, 2009 to YTD 2015 66
Bayer AG, Petrochemicals, Deals By Type, 2009 to YTD 2015 67
Bayer AG, Power, Deals By Year, 2009 to YTD 2015 68
Bayer AG, Power, Deals By Type, 2009 to YTD 2015 69
Bayer AG, Recent Deals Summary 70
Section 5 - Company's Recent Developments 71
Aug 27, 2015: CINDE Announces: Bayer Opened Its First Medical Devices Plant in Costa Rica 71
Jul 29, 2015: Bayer Significantly Improves Earnings 72
Jun 19, 2015: Bayer Plans To Invest €4 Billion In RandD In 2015 75
Jun 18, 2015: One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015 76
Jun 15, 2015: Bayer to Present Latest Advances in Hemophilia Research at the ISTH 2015 Annual Congress in Toronto 77
May 27, 2015: Bayer has outstanding perspectives as a pure Life Science company 79
Apr 30, 2015: Strong start to the year for Bayer 81
Mar 11, 2015: Bayer aspires to significantly expand Life Science businesses 84
Feb 26, 2015: Bayer: strong business momentum continues and portfolio transformation underway 85
Feb 25, 2015: Dr. Richard Pott to be Chairman of the Supervisory Board of Bayer MaterialScience 88
Section 6 - Appendix 89
Methodology 89
Ratio Definitions 89
About GlobalData 93
Contact Us 94
Disclaimer 94

List of Tables
Bayer AG, Key Facts 6
Bayer AG, Key Employees 7
Bayer AG, Key Employee Biographies 10
Bayer AG, Major Products and Services 11
Bayer AG, Number of Pipeline Products by Therapy Area 14
Bayer AG, Number of Pipeline Products by Development Stage 15
Bayer AG, Pipeline Products By Therapy Area and Development Phase 16
Bayer AG, History 23
Bayer AG, Subsidiaries 38
Bayer AG, Joint Venture 48
Bayer AG, Key Competitors 57
Bayer AG, Ratios based on current share price 58
Bayer AG, Annual Ratios 59
Bayer AG, Interim Ratios 62
Bayer AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 64
Bayer AG, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 65
Bayer AG, Petrochemicals, Deals By Year, 2009 to YTD 2015 66
Bayer AG, Petrochemicals, Deals By Type, 2009 to YTD 2015 67
Bayer AG, Power, Deals By Year, 2009 to YTD 2015 68
Bayer AG, Power, Deals By Type, 2009 to YTD 2015 69
Bayer AG, Recent Deals Summary 70
Currency Codes 89
Units 89
Capital Market Ratios 89
Equity Ratios 90
Profitability Ratios 90
Cost Ratios 91
Liquidity Ratios 91
Leverage Ratios 92
Efficiency Ratios 92

List of Figures
Bayer AG, Pipeline Products by Therapy Area 14
Bayer AG, Pipeline Products by Development Phase 15
Bayer AG, Performance Chart (2010 - 2014) 61
Bayer AG, Ratio Charts 63
Bayer AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 64
Bayer AG, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 65
Bayer AG, Petrochemicals, Deals By Year, 2009 to YTD 2015 66
Bayer AG, Petrochemicals, Deals by Type, 2009 to YTD 2015 67
Bayer AG, Power, Deals By Year, 2009 to YTD 2015 68
Bayer AG, Power, Deals by Type, 2009 to YTD 2015 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
A 33-Country Survey of the Infectious Disease Testing Market: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

A 33-Country Survey of the Infectious Disease Testing Market: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

  • $ 54 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any othe ...

A 33-Country Survey of the Immunodiagnostics Market: Sales Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Supplier Shares, Competitive Strategies, Opportunities

A 33-Country Survey of the Immunodiagnostics Market: Sales Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Supplier Shares, Competitive Strategies, Opportunities

  • $ 47 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 ...

A 33-Country Survey of the Automated Microbiology Market: Supplier Shares, Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

A 33-Country Survey of the Automated Microbiology Market: Supplier Shares, Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from ...

Cancer Bundle

January 2016 $ 24 225

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.